Breaking News, Collaborations & Alliances

Abcam, Merck Launch Anti-PD-L1 Antibody Clone

MKP1A07310 (clone 73-10) for Immuno-Oncology research

Abcam announced the commercial launch of the new anti-PD-L1 antibody clone MKP1A07310 (clone 73-10) developed in collaboration with Merck KGaA, Darmstadt, Germany. Developed by Abcam for use by Merck as an analytical antibody to support Merck’s therapeutic program several years ago, this new clone has been created by Abcam’s in-house antibody engineers, who specialize in the discovery and development of challenging antibodies. The antibody is important in assessing the expression of PD-L1 in ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters